Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Alexey V DanilovCharles HerbauxHarriet Sarah WalterPeter HillmenSimon A RuleEbenezer A KioLionel KarlinMartin J S DyerSiddhartha S MitraPing Cheng YiRita HumeniukXi HuangZiqian ZhouPankaj BhargavaJuliane M JürgensmeierChristopher D FeganPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Tirabrutinib in combination with idelalisib or entospletinib was well tolerated in patients with CLL, establishing an acceptable safety profile for concurrent selective inhibition of BTK with either PI3Kδ or SYK. This small study did not establish a superior efficacy of the combinations over tirabrutinib alone. This trial is registered at www.clinicaltrials.gov (NCT02457598).